Menu
Search
|

Menu

Close
X

DexCom Inc DXCM.OQ (NASDAQ Stock Exchange Global Select Market)

146.85 USD
-1.05 (-0.71%)
As of 10:25 AM EST
chart
Previous Close 147.90
Open 147.09
Volume 55,152
3m Avg Volume 477,746
Today’s High 147.95
Today’s Low 146.38
52 Week High 155.76
52 Week Low 53.31
Shares Outstanding (mil) 88.84
Market Capitalization (mil) 13,140.08
Forward P/E 87.78
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.85 Mean rating from 20 analysts

KEY STATS

Revenue (mm, USD)
FY18
694
FY17
719
FY16
573
EPS (USD)
FY18
0.577
FY17
0.629
FY16
-0.787
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
87.78
36.18
Price to Sales (TTM)
vs sector
14.37
10.03
Price to Book (MRQ)
vs sector
23.36
4.56
Price to Cash Flow (TTM)
vs sector
75.69
26.61
Total Debt to Equity (MRQ)
vs sector
61.56
16.56
LT Debt to Equity (MRQ)
vs sector
61.56
13.03
Return on Investment (TTM)
vs sector
18.10
12.67
Return on Equity (TTM)
vs sector
31.47
13.70

EXECUTIVE LEADERSHIP

Kevin Sayer
Chairman of the Board, President, Chief Executive Officer, Since 2018
Salary: $546,250.00
Bonus: $996,906.00
Quentin Blackford
Chief Financial Officer, Executive Vice President, Since 2017
Salary: $150,000.00
Bonus: $369,563.00
Donald Abbey
Executive Vice President - Quality and Regulatory Affairs, Since 2017
Salary: $355,300.00
Bonus: $389,054.00
Andrew Balo
Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development, Since 2016
Salary: $355,300.00
Bonus: $389,054.00
Richard Doubleday
Executive Vice President, Chief Commercial Officer, Since 2015
Salary: $355,300.00
Bonus: $389,054.00

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

6340 Sequence Dr
SAN DIEGO   CA   92121-4356

Phone: +1858.2000200

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

SPONSORED STORIES